T2 Biosystems (TTOO) Announces Presentation of Data on T2MR Tech in Lyme Disease
- Stocks dip as earnings pour in, consumer discretionary lags
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Twitter (TWTR) Tops Q3 EPS by 4c; Announces Restructuring, Workforce Reduction
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
T2 Biosystems, Inc. (Nasdaq: TTOO) announced that Tom Lowery, Ph.D., chief scientific officer, today presented data on the T2 Magnetic Resonance (T2MR®) technology for the detection of Borrelia – the bacteria that causes Lyme disease – directly from whole blood samples. The data were presented at the Diagnostic Tests for Lyme Disease Conference at the Banbury Center at Cold Spring Harbor Laboratory in New York.
Dr. Lowery’s Lyme disease presentation included limit of detection data of <10 cells/mL and data demonstrating T2MR detection of Borrelia in samples from patients in early stages of the disease. In addition, Dr. Lowery presented results from previously reported studies of the Company’s T2Candida® and T2Bacteria™ Panels, including limit of detection data for the T2Bacteria Panel of <5 CFU/mL.
“According to the CDC, roughly 30,000 cases of Lyme disease are reported in the U.S. each year; yet, the current diagnostic testing market remains poor. Patients are frequently misdiagnosed or face delayed diagnosis, and there are almost 300,000 patients that are undiagnosed, despite over 3 million tests run annually in the U.S. alone,” said John McDonough, president and CEO of T2 Biosystems. “The data presented at Cold Spring Harbor Laboratory illustrate the early success of our T2MR technology in this area of important unmet medical need, including its ability to rapidly detect Borrelia without the need for blood culture. A timely diagnosis of Lyme disease may help prevent the evolution of the disease to its later stages, and ultimately, eliminate the significant costs associated with these effects. We look forward to further developing this technology and eventually introducing the T2Lyme™ Panel, a test we’re developing in partnership with our partner, Canon U.S. Life Sciences.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EQT Corp. (EQT) Tops Q3 EPS by 15c; Announces CEO Succession
- Amedisys (AMED) Prelim. Q3 EPS Misses Views
- Avid Technology (AVID) Enters Licensing Agreement with Nexidia for Media, Entertainment Rights
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!